<PAGE>

                                  FORM 10-Q


                      SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D.C.  20549

[x]  Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
      Act of 1934
For the quarterly period ended SEPTEMBER 30, 1996 or

[ ]  Transition report pursuant to section 13 or 15(d) of the Securities 
     Exchange Act of 1934
For the transition period from ______ to ______

                                    1-9731
                             (COMMISSION FILE NO.)

                      ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


                DELAWARE                                72-0925679
    (STATE OR OTHER JURISDICTION OF                  (I.R.S. EMPLOYER
     INCORPORATION OR ORGANIZATION)                  IDENTIFICATION NO.)


        5910 COURTYARD DRIVE #300
               AUSTIN, TEXAS                               78731
  (ADDRESS OF PRINCIPAL EXECUTIVE OFFICE)                (ZIP CODE)


                                 (512) 343-6912
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

Indicate by check mark whether the registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 
1934 during the preceding 12 months (or for such shorter period that the 
registrant was required to file such reports), and (2) has been subject to 
such filing requirements for the past 90 days. Yes  X  No   . 
                                                   ---   ---  

As of November 1, 1996 there were 3,563,101 shares of common stock outstanding.

This report consists of 9 pages.


<PAGE>

                     ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

                              TABLE OF CONTENTS

                                  FORM 10-Q

                              September 30, 1996

PART I - FINANCIAL INFORMATION..............................................  3

  Item 1.  Financial Statements.............................................  3

  CONSOLIDATED BALANCE SHEETS...............................................  3

  CONSOLIDATED STATEMENTS OF INCOME.........................................  4

  CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY................  5

  CONSOLIDATED STATEMENTS OF CASH FLOWS.....................................  6

  SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS...................  7

  Item 2.  Management's Discussion and Analysis of 
           Financial Condition and Results of Operations....................  7

PART II - OTHER INFORMATION.................................................  9

  Item 1.  Legal Proceedings - none.........................................  9

  Item 2.  Changes in Securities - none.....................................  9

  Item 3.  Defaults Upon Senior Securities - none...........................  9

  Item 4.  Submission of Matters to a Vote of Security Holders - none.......  9

  Item 5.  Other Information - none.........................................  9

  Item 6.  Exhibits and Reports on Form 8-K - none..........................  9

SIGNATURES..................................................................  9




                                 Page 2 of 9

<PAGE>
                        PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

              ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                          CONSOLIDATED BALANCE SHEETS 

<TABLE>
                                                                                               (Unaudited)
                                                                                               September 30,  December 31,
                                               ASSETS                                              1996           1995
                                                                                               ------------   ------------ 
<S>                                                                                            <C>             <C>
Current assets:
  Cash and cash equivalents..................................................................  $    157,516   $    397,799 
  Trade accounts receivable, net of allowance for doubtful accounts of $18,864 and $18,820...     4,734,476      3,739,046 
  Inventories................................................................................     1,973,306      2,991,346 
  Deposits...................................................................................        54,000         58,000 
  Prepaid expenses and other current assets..................................................       204,799        283,184 
                                                                                               ------------   ------------ 
    Total current assets.....................................................................     7,124,097      7,469,375 

Property and equipment, net of accumulated depreciation of $1,596,969 and $1,263,364.........     3,030,509      2,591,888 
Patent costs, net of accumulated amortization of $173,036 and $157,222.......................        98,131        100,727 
Software development costs, net of accumulated amortization of $212,873 and $199,280.........         4,545         15,638 
Goodwill, net of accumulated amortization of $475,732 and $389,584...........................     1,847,341      1,933,489 
Deferred income taxes........................................................................       670,683        670,683 
Other .......................................................................................       170,079        186,235 
                                                                                               ------------   ------------ 
   Total assets..............................................................................  $ 12,945,386   $ 12,968,035 
                                                                                               ------------   ------------ 
                                                                                               ------------   ------------ 

                                    LIABILITIES AND SHAREHOLDERS' EQUITY 

Current liabilities: 
  Revolving credit facilities................................................................  $  1,484,598   $  1,938,972 
  Current maturities of long-term debt.......................................................       172,069        199,486 
  Accounts payable...........................................................................     1,821,547      2,105,928 
  Income taxes payable.......................................................................       239,045             -  
  Payable to related parties.................................................................            -          30,899 
  Accrued liabilities........................................................................       383,733        390,981 
                                                                                               ------------   ------------ 
    Total current liabilities................................................................     4,100,992      4,666,266 
Long-term debt, net of current maturities....................................................       412,278        491,930 
Bonds payable................................................................................       426,500        398,000 
Deferred revenue.............................................................................        93,770         49,048 
                                                                                               ------------   ------------ 
    Total liabilities........................................................................     5,033,540      5,605,244 
                                                                                               ------------   ------------ 
Commitments & Contingencies..................................................................            -              -  
Redeemable common stock......................................................................            -          10,046 
                                                                                               ------------   ------------ 
Shareholders' equity: 
  Serial preferred stock, $1 par value; 2,000,000 shares authorized, none issued.............            -              -  
  Common stock, $.01 par value; 10,000,000 shares authorized; 
  3,679,216 and 3,679,216 issued.............................................................        36,792         36,792 
Additional paid-in-capital...................................................................     8,909,307      8,899,261 
Treasury stock...............................................................................      (878,787)      (868,740)
Unearned ESOP compensation...................................................................      (135,705)      (167,848)
Retained deficit.............................................................................       (19,761)      (546,720)
                                                                                               ------------   ------------ 
    Total shareholders' equity...............................................................     7,911,846      7,352,745 
                                                                                               ------------   ------------ 
    Total liabilities and shareholders' equity...............................................  $ 12,945,386   $ 12,968,035 
                                                                                               ------------   ------------ 
                                                                                               ------------   ------------ 
</TABLE>

The accompanying notes are an integral part of the consolidated financial
statements.

                                  Page 3 of 9
<PAGE>

               ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                       CONSOLIDATED STATEMENTS OF INCOME
                                (Unaudited)

<TABLE>
                                       Three months ended September 30,  Nine months ended September 30,
                                       --------------------------------  ------------------------------
                                             1996            1995            1996              1995
                                       ------------      ------------    -------------    -------------

<S>                                    <C>                <C>             <C>              <C>
Sales................................. $  6,464,147      $  4,975,378    $  18,567,323    $  17,463,992
Cost of sales.........................    5,112,182         3,864,946       14,962,270       13,723,228
                                       ------------      ------------    -------------    -------------
Gross profit..........................    1,351,966         1,110,432        3,605,053        3,740,764
                                       ------------      ------------    -------------    -------------
Selling and marketing.................      159,779           99,532           456,873          321,430
General and administrative............      541,433          514,978         1,692,823        1,530,750
Research and development..............       41,368           47,158           126,596          138,795
Amortization of goodwill..............       28,716           28,716            86,148           86,148
                                       ------------      ------------    -------------    -------------
Total Expenses........................      771,296          690,384         2,362,440        2,077,123
                                       ------------      ------------    -------------    -------------
Income from operations................      580,670          420,048         1,242,613        1,663,641
                                       ------------      ------------    -------------    -------------
Other income (expense):
  Interest expense....................      (67,338)         (65,309)         (211,733)        (190,537)
  Gain on sale of stock...............         -                -                 -              72,912
  Other...............................       (3,953)            (979)           (7,313)           1,429
                                       ------------      ------------    -------------    -------------
Income before income taxes............      509,379          353,760         1,023,567        1,547,445
Income taxes..........................     (227,632)        (154,972)         (496,609)        (644,193)
                                       ------------      ------------    -------------    -------------
Net income............................ $    281,747      $    198,788    $     526,958    $     903,252
                                       ------------      ------------    -------------    -------------
                                       ------------      ------------    -------------    -------------

Net income per share.................. $       0.08      $       0.06    $        0.15    $        0.25
                                       ------------      ------------    -------------    -------------
                                       ------------      ------------    -------------    -------------

Weighted average number of common
  and dilutive common equivalent
  shares outstanding..................    3,563,101         3,606,382        3,563,414        3,644,321
                                       ------------      ------------    -------------    -------------
                                       ------------      ------------    -------------    -------------
</TABLE>

     The accompanying notes are an integral part of the financial statements



                                  Page 4 of 9
<PAGE>
                                      
            ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY 
        CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY 

<TABLE>
                                                                                                 Retained   
                                  Common Shares                                   Unearned       Earnings   
                               --------------------    Paid-in      Treasury      ESOP         (Accumulated 
                               Outstanding   Amount    Capital       Stock      Compensation      Deficit)      Total    
                               -----------  -------   ----------    ---------   ------------   ------------  ----------- 
<S>                            <C>          <C>       <C>           <C>         <C>            <C>           <C>         
January 1, 1994..............   3,657,216   $36,572   $7,378,486                 $(253,564)    $ 1,803,214   $ 8,964,708 
Exercise of options..........       5,000        50       19,950                                                  20,000 
Maturity and repurchases of
 redeemable common stock.....                            603,863                                                 603,863 
ESOP payments................                                                       42,859                        42,859 
Treasury stock purchase......     (49,181)                          $(363,939)                                  (363,939)
Unrealized securities gain...                                                                                          0 
Net loss.....................                                                                   (3,475,160)   (3,475,160)
                                ---------   -------   ----------    ---------    ---------     -----------   ----------- 
December 31, 1994............   3,613,035    36,622    8,002,299     (363,939)    (210,705)     (1,671,946)    5,792,331 
Exercise of options..........      17,000       170       67,830                                                  68,000 
Issuance of warrants.........                            202,000                                                 202,000 
Maturity and repurchases of
 redeemable common stock.....                            627,132                                                 627,132 
ESOP Payments................                                                       42,857                        42,857 
Treasury stock purchase......     (65,524)                           (504,801)                                  (504,801)
Sale of securities...........                                                                                          0 
Net income...................                                                                    1,125,226     1,125,226 
                                ---------   -------   ----------    ---------    ---------     -----------   ----------- 
December 31, 1995............   3,564,511    36,792    8,899,261     (868,740)    (167,848)       (546,720)    7,352,745 
Repurchase of redeemable
 common stock................                             10,046                                                  10,046 
Treasury stock purchase......      (1,410)                            (10,047)                                   (10,047)
ESOP Payments................                                                       32,143                        32,143 
Net income...................                                                                      526,958       526,958 
                                ---------   -------   ----------    ---------    ---------     -----------   ----------- 
September 30, 1996 
 (Unaudited).................   3,563,101   $36,792   $8,909,307    $(878,787)   $(135,705)    $   (19,761)  $ 7,911,846 
                                ---------   -------   ----------    ---------    ---------     -----------   ----------- 
                                ---------   -------   ----------    ---------    ---------     -----------   ----------- 
</TABLE>

                 The accompanying notes are an integral part 
                  of the consolidated financial statements.  












                                Page 5 of 9 
<PAGE>

            ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY 
                    CONSOLIDATED STATEMENTS OF CASH FLOWS 
                                 (Unaudited) 


                                                           Nine months ended    
                                                             September 30,      
                                                         ---------------------- 
                                                           1996         1995    
                                                         ---------    --------- 
Cash flows provided by (used in) operating activities: 
  Net income..........................................   $ 526,958    $ 903,252 
  Adjustments to reconcile net income to net cash: 
    Depreciation......................................     333,604      353,017 
    Amortization......................................     115,555      129,999 
    Gain on sales of investments......................           -      (72,912)
    Deferred revenue..................................      44,722      (12,579)
  Changes in assets and liabilities: 
    Accounts receivable...............................    (995,430)     (49,998)
    Deposits..........................................       4,000        8,000 
    Inventory.........................................   1,018,040       38,777 
    Accounts payable and accrued expenses.............    (291,629)    (416,613)
    Income taxes payable..............................     239,045
    Payable to related parties........................     (30,899)     (15,470)
    Other.............................................     123,075       35,634 
                                                         ---------    --------- 
Net cash provided by operating activities.............   1,087,041      901,107 
                                                         ---------    --------- 
Cash flows provided by (used in) investing activities: 
  Proceeds from sale of short-term investments........           -      119,787 
  Software expenditures...............................      (2,500)
  Capital expenditures................................    (584,458)    (244,760)
  Patent expenditures.................................     (13,218)     (12,650)
                                                         ---------    --------- 
    Net cash used in investing activities.............    (600,176)    (137,623)
                                                         ---------    --------- 
Cash flows provided by (used in) financing activities: 
  Net repayments of revolving credit facilities.......    (454,374)    (287,035)
  Repayment of notes payable..........................           -     (253,000)
  Proceeds from issuance of bonds payable.............           -      600,000 
  Proceeds from issuance of common stock..............           -       68,000 
  Purchase of treasury stock..........................     (10,047)    (386,769)
  Reduction of unearned ESOP compensation.............      32,143       28,571 
  Principal payments on long-term debt................    (294,870)    (301,961)
                                                         ---------    --------- 
    Net cash used in financing activities.............    (727,148)    (532,194)
                                                         ---------    --------- 
Net increase (decrease) in cash and cash equivalents..    (240,283)     231,290 
Cash and cash equivalents at beginning of period......     397,799       22,790 
                                                         ---------    --------- 
Cash and cash equivalents at end of period............   $ 157,516    $ 254,080 
                                                         ---------    --------- 
                                                         ---------    --------- 



The accompanying notes are an integral part of the financial statements 















                                Page 6 of 9 
<PAGE>

SUPPLEMENTAL NOTES TO FINANCIAL STATEMENTS

   The unaudited interim consolidated financial statements and related notes 
have been prepared pursuant to the rules and regulations of the Securities 
and Exchange Commission.  Accordingly, certain information and footnote 
disclosures normally included in financial statements prepared in accordance 
with generally accepted accounting principles have been omitted pursuant to 
such rules and regulations.  The accompanying unaudited interim consolidated 
financial statements and related notes should be read in conjunction with the 
consolidated financial statements and notes thereto included in the Company's 
most recent Form 10-K covering the year ended December 31, 1995.

   The information furnished reflects, in the opinion of the management of 
Arrhythmia Research Technology, Inc. ("ART"), all adjustments necessary for a 
fair presentation of the financial results for the interim period presented.

   Interim results are subject to year-end adjustments and audit by 
independent certified public accountants.

INVENTORIES:

   Inventories consist of the following as of:

                                                    SEPTEMBER 30,  DECEMBER 31,
                                                        1996           1995
                                                    -------------  ------------
     Raw materials...............................   $   416,144     $   467,895
     Work-in-process.............................       215,190         277,296
     Finished goods..............................     2,443,258       3,359,407
                                                    -----------     -----------
       Total.....................................     3,074,592       4,104,598
     Allowance for slow-moving inventories.......    (1,101,286)     (1,113,252)
                                                    -----------     -----------
       Total.....................................   $ 1,973,306     $ 2,991,346
                                                    -----------     -----------
                                                    -----------     -----------

PROPERTY, PLANT & EQUIPMENT:

   In September 1996, Micron completed the purchase of a building adjacent to 
the current manufacturing facility ("the Century building").  The purchase 
price of the Century building was $480,000.  Micron paid $380,000 in cash and 
financed the balance through a capital lease of $100,000 with the building's 
current owner.  The building is subject to the typical  environmental 
monitoring and reporting for a building in the area.  Micron has received an 
indemnification for the first $200,000 of environmental costs other than 
normal monitoring and reporting expenditures from the seller of the Century 
building. The Company and its environmental engineering firm believe that the 
idemnification and the Company's reserves are sufficient to cover any 
possible potential future environmental remediation costs. The Company 
expenses the costs of ongoing environmental monitoring and reporting in the 
period in which they occur.

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND 
          RESULTS OF OPERATIONS

LIQUIDITY AND CAPITAL RESOURCES

   At September 30, 1996, the Company had working capital of approximately 
$3,023,000.  At September 30, 1996, the Company has a $3,500,000 working 
capital line of credit with a bank, collateralized by accounts receivable and 
inventory of ART and Micron Products Inc., which bears interest at prime plus 
 .75% (9% at September 30, 1996).  The working capital line of credit matures 
September 30, 1997 and had an outstanding balance of approximately $1,485,000 
at September 30, 1996.  The Company's lines of credit are its primary source 
of operating funds and liquidity.

   Capital expenditures during the first nine months of 1996 were 
approximately $772,000 (including approximately $188,000 of capital 
expenditures added through capital leases) as compared to $245,000 in 1995.  
Capital expenditures have increased significantly due to the purchase of the 
Century building.  The purchase price of the Century building was $480,000.  
Micron paid $380,000 in cash and financed the balance through a capital lease 
of $100,000 with the building's current owner.  The remaining capital 
expenditures during 1996 consist of the purchase of a K3 Cath-Lab 
demonstration system by ART and normal capital equipment expenditures for the 
manufacturing facility in Fitchburg, Massachusetts.  Micron has also incurred 
preliminary design and testing costs for a proposed new waste-water treatment 
and filtration system which will be installed in the Century building in the 
next twelve months.  Capital expenditures are expected to be higher in 1996 
than they were in 1995.  Normal capital expenditures are funded from 
operating cash flows and capital projects, such as the proposed new 
waste-water treatment and filtration system are typically financed by capital 
equipment leases.

RESULTS OF OPERATIONS

   REVENUES for the third quarter ended September 30, 1996 increased 30% when 
compared to the third quarter ended September 30, 1995, and revenues for the 
nine months ended September 30, 1996 increased 6% as compared to the same 


                             Page 7 of 9
<PAGE>

period of the prior year.  CardioLab and CardioMapp ("EP") product revenues 
increased 19% for the quarter ended September 30, 1996 as compared to 1995.  
EP product revenues increased 3% for the nine months ended September 30, 1996 
as compared to the same period in 1995.  Sales of EP products in 1996 are 
expected to be consistent with the prior year.  However, 1996 will be the 
final year in which ART will act as the exclusive distributor for EP products 
under its contract with their manufacturer, Prucka Engineering, Inc.  In 
1997, ART will not report the gross revenues nor the related cost of sales 
for EP products which approximated $10,759,000 and $9,869,000 for the nine 
months ended September 30, 1996 and $10,431,000 and $9,267,000 for the nine 
months ended September 30, 1995.  During 1997, ART will receive a 4% 
commission on net sales of EP systems and accessories sold anywhere in the 
world, up to a ceiling of $10,000,000 in total annual net sales. During 1998, 
ART will receive a commission of 4% on CardioLab systems sold anywhere in the 
world, up to a ceiling of $10,000,000 in total annual net sales. From January 
1, 1999 through December 31, 2002, ART will receive a commission of 3% of the 
net sales of CardioLab systems sold anywhere in the world, up to a ceiling of 
$10,000,000 in total net sales.

   Revenues from sales of ECG sensors increased 50% and 10% for the quarter 
and nine months ended September 30, 1996, as compared to the same periods in 
1995.  The increase in sensor sales is due to increased demand in the 
domestic market.  Pricing on all products remained approximately the same for 
the third quarter and first nine months of 1996 as compared to 1995.  The 
sales mix for the Company has remained stable with electrophysiology product 
systems and ECG sensors making up most sales and the related cost of sales.

                         THIRD QUARTER                  FIRST NINE MONTHS
                ------------------------------  --------------------------------
                   1996      %     1995      %      1996      %     1995       %
                ---------- ---  ---------- ---  ----------- ---  ----------- ---
Domestic......  $4,452,075  69  $3,961,324  80  $12,328,202  66  $12,677,999  73
Foreign.......   2,012,072  31   1,014,054  20    6,239,121  34    4,785,993  27
                ---------- ---  ---------- ---  ----------- ---  ----------- ---
Total.........  $6,464,147 100  $4,975,378 100  $18,567,323 100  $17,463,992 100
                ---------- ---  ---------- ---  ----------- ---  ----------- ---
                ---------- ---  ---------- ---  ----------- ---  ----------- ---

      COST OF SALES increased slightly for the quarter and nine months ended 
September 30, 1996, as compared to the same periods in 1995.  The cost of 
components has increased as the majority of cost of sales is made up of EP 
systems, which are purchased at a pre-determined price under contract from 
the manufacturer.  The contract contained a price increase from 1995 to 1996, 
thereby increasing the cost of the systems in 1996 resulting in higher cost 
of sales.  Overhead costs for the third quarter ended September 30, 1996, 
decreased as compared to the same period of the prior year due to lower than 
normal overtime, maintenance, and utility costs.  Overhead costs have 
remained consistent for the nine months September 30, 1996 as compared to 
1995.  Cost of sales as a percent of sales is expected to remain similar for 
the remainder of the year.  The following table details the make-up of cost 
of sales between overhead and component costs:


                         THIRD QUARTER                  FIRST NINE MONTHS
                ------------------------------  --------------------------------
                   1996      %     1995      %      1996      %     1995       %
                ---------- ---  ---------- ---  ----------- ---  ----------- ---
Components....  $4,727,598  73  $3,457,912  70  $13,777,791  74  $12,543,162  72
Overhead......     384,584   6     407,034   8    1,184,479   6    1,180,066   7
                ---------- ---  ---------- ---  ----------- ---  ----------- ---
Total.........  $5,112,182  79  $3,864,946  78  $14,962,270  80  $13,723,228  79
                ---------- ---  ---------- ---  ----------- ---  ----------- ---
                ---------- ---  ---------- ---  ----------- ---  ----------- ---

   SELLING AND MARKETING expenses have increased in gross dollars and as a 
percent of sales during the third quarter and nine months ended September 30, 
1996 as compared to the same periods for 1995.  The increase is due to lower 
than normal personnel costs during the first nine months of 1995 and 
increased marketing activity related to the Astro-Med/ART K3 cardiac 
catheterization Lab.  The primary components of marketing and selling 
expenses for the third quarter and nine months ended September 30, 1996 are 
salaries and trade show expenses.  The current level of marketing operations 
is expected to continue for the remainder of the year. 

   GENERAL AND ADMINISTRATIVE expenses have remained comparable for the third 
quarter ended September 30, 1996, as compared to 1995.  The increase in 
general and administrative expenses for the nine months ended September 30, 
1996 as compared to 1995 is due to higher environmental monitoring costs and 
debt cost amortization.  The primary components of general and administrative 
expenses are salaries and related payroll taxes and benefits, environmental 
monitoring expenses, professional fees, and insurance costs.  General and 
administrative expenses are expected to continue at this level for the 
remainder of the year.

   RESEARCH AND DEVELOPMENT expenses have decreased slightly for the third 
quarter and nine months ended September 30, 1996, as compared to the same 
periods in 1995.  The decrease is due primarily to lower travel costs.  The 
thrust of the research and development effort is to develop new software 
applications for existing signal averaging products and new products 
utilizing the patented Simson method of signal averaging.


                             Page 8 of 9
<PAGE>

                   PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS - NONE

ITEM 2.  CHANGES IN SECURITIES - NONE

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES - NONE

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - NONE

ITEM 5.  OTHER INFORMATION - NONE 

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K - NONE

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.
 
                                  ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
                                  ------------------------------------

                                  /s/ E. P. Marinos

                                  E. P. Marinos, President and
                                  Chief Executive and Financial Officer


                                  /s/  Anthony A. Cetrone,
                                  President, Micron Products Inc.

November 12, 1996 





                                   Page 9 of 9